Does the media refer more to EWTX or GMAB?

In the previous week, Edgewise Therapeutics had 4 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Edgewise Therapeutics and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Edgewise Therapeutics' score of 0.13 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASND or EWTX?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Edgewise Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.32 beat Edgewise Therapeutics' score of 0.13 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EWTX or BBIO?

In the previous week, BridgeBio Pharma had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 14 mentions for BridgeBio Pharma and 6 mentions for Edgewise Therapeutics. BridgeBio Pharma's average media sentiment score of 0.75 beat Edgewise Therapeutics' score of 0.13 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EWTX or ELAN?

In the previous week, Elanco Animal Health had 7 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Elanco Animal Health and 6 mentions for Edgewise Therapeutics. Elanco Animal Health's average media sentiment score of 0.90 beat Edgewise Therapeutics' score of 0.13 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SMMT or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A

Is SMMT or EWTX more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Edgewise Therapeutics N/A -32.55% -31.04%

Does the media refer more to SMMT or EWTX?

In the previous week, Summit Therapeutics had 13 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for Summit Therapeutics and 6 mentions for Edgewise Therapeutics. Summit Therapeutics' average media sentiment score of 0.60 beat Edgewise Therapeutics' score of 0.13 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Edgewise Therapeutics (EWTX) Competitors

$32.92 -1.14 (-3.35%)

Closing price 04:00 PM Eastern

Extended Trading

$32.92 -0.01 (-0.02%)

As of 06:09 PM Eastern

Compare

EWTX vs. GMAB, ASND, BBIO, ELAN, and SMMT

Should you buy Edgewise Therapeutics stock or one of its competitors? MarketBeat compares Edgewise Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edgewise Therapeutics include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Edgewise Therapeutics compare to Genmab A/S?

Edgewise Therapeutics (NASDAQ:EWTX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Edgewise Therapeutics currently has a consensus target price of $44.22, indicating a potential upside of 34.33%. Genmab A/S has a consensus target price of $37.93, indicating a potential upside of 54.87%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Edgewise Therapeutics had 4 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Edgewise Therapeutics and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Edgewise Therapeutics' score of 0.13 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Genmab A/S	$3.72B	4.10	$963M	$1.32	18.55

Genmab A/S has a net margin of 21.05% compared to Edgewise Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Genmab A/S	21.05%	15.34%	8.94%

7.1% of Genmab A/S shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

Genmab A/S beats Edgewise Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Ascendis Pharma A/S currently has a consensus price target of $295.39, indicating a potential upside of 40.80%. Edgewise Therapeutics has a consensus price target of $44.22, indicating a potential upside of 34.33%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Edgewise Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.32 beat Edgewise Therapeutics' score of 0.13 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a net margin of 57.87% compared to Edgewise Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Edgewise Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	16.07	-$258M	$8.67	24.20
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Summary

Ascendis Pharma A/S beats Edgewise Therapeutics on 13 of the 14 factors compared between the two stocks.

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Edgewise Therapeutics (NASDAQ:EWTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, BridgeBio Pharma had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 14 mentions for BridgeBio Pharma and 6 mentions for Edgewise Therapeutics. BridgeBio Pharma's average media sentiment score of 0.75 beat Edgewise Therapeutics' score of 0.13 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Edgewise Therapeutics presently has a consensus target price of $44.22, indicating a potential upside of 34.33%. BridgeBio Pharma has a consensus target price of $89.59, indicating a potential upside of 32.92%. Given Edgewise Therapeutics' higher probable upside, equities analysts clearly believe Edgewise Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Edgewise Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Edgewise Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
BridgeBio Pharma	$502.08M	26.29	-$724.93M	-$3.74	N/A

99.9% of BridgeBio Pharma shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

BridgeBio Pharma beats Edgewise Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Elanco Animal Health?

Edgewise Therapeutics (NASDAQ:EWTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Elanco Animal Health had 7 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Elanco Animal Health and 6 mentions for Edgewise Therapeutics. Elanco Animal Health's average media sentiment score of 0.90 beat Edgewise Therapeutics' score of 0.13 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Edgewise Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Elanco Animal Health	$4.72B	2.43	-$232M	-$0.50	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Elanco Animal Health	-4.95%	7.42%	3.66%

Edgewise Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Edgewise Therapeutics currently has a consensus price target of $44.22, indicating a potential upside of 34.33%. Elanco Animal Health has a consensus price target of $28.20, indicating a potential upside of 22.90%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Edgewise Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Elanco Animal Health beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

In the previous week, Summit Therapeutics had 13 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for Summit Therapeutics and 6 mentions for Edgewise Therapeutics. Summit Therapeutics' average media sentiment score of 0.60 beat Edgewise Therapeutics' score of 0.13 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.6% of Summit Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Edgewise Therapeutics' return on equity of -32.55% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Summit Therapeutics currently has a consensus price target of $26.05, suggesting a potential upside of 99.65%. Edgewise Therapeutics has a consensus price target of $44.22, suggesting a potential upside of 34.33%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Summary

Summit Therapeutics beats Edgewise Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Edgewise Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EWTX vs. The Competition

Export

Metric	Edgewise Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.54B	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-19.83	18.99	24.49	23.62
Price / Sales	N/A	290.48	500.49	105.27
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	6.68	8.00	10.43	6.70
Net Income	-$167.79M	$23.89M	$3.56B	$337.26M
7 Day Performance	-9.21%	-3.49%	-1.38%	-1.41%
1 Month Performance	-6.80%	1.02%	0.86%	1.15%
1 Year Performance	113.07%	34.39%	19.43%	22.61%

Edgewise Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EWTX Edgewise Therapeutics	2.5709 of 5 stars	$32.92 -3.3%	$44.22 +34.3%	+123.2%	$3.54B	N/A	N/A	60
GMAB Genmab A/S	4.4615 of 5 stars	$23.85 -6.3%	$37.93 +59.0%	+12.8%	$14.87B	$3.90B	18.07	3,029
ASND Ascendis Pharma A/S	4.6953 of 5 stars	$216.60 -1.0%	$295.39 +36.4%	+23.1%	$13.51B	$865.78M	24.98	1,189	Positive News Analyst Forecast
BBIO BridgeBio Pharma	3.5538 of 5 stars	$63.88 -2.3%	$88.90 +39.2%	+73.4%	$12.51B	$579.96M	N/A	400	Insider Trade
ELAN Elanco Animal Health	3.8237 of 5 stars	$23.65 -0.1%	$28.20 +19.2%	+75.6%	$11.81B	$4.89B	N/A	9,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EWTX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. GMAB, ASND, BBIO, ELAN, and SMMT

How does Edgewise Therapeutics compare to Genmab A/S?

Summary

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Summary

How does Edgewise Therapeutics compare to Elanco Animal Health?

Summary

How does Edgewise Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. GMAB, ASND, BBIO, ELAN, and SMMT

How does Edgewise Therapeutics compare to Genmab A/S?

Do analysts prefer EWTX or GMAB?

Does the media refer more to EWTX or GMAB?

Which has higher valuation and earnings, EWTX or GMAB?

Is EWTX or GMAB more profitable?

Do insiders and institutionals hold more shares of EWTX or GMAB?

Which has more risk & volatility, EWTX or GMAB?

Summary

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Do analysts recommend ASND or EWTX?

Which has more volatility & risk, ASND or EWTX?

Does the media favor ASND or EWTX?

Is ASND or EWTX more profitable?

Which has higher earnings & valuation, ASND or EWTX?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Does the media favor EWTX or BBIO?

Which has more risk & volatility, EWTX or BBIO?

Do analysts recommend EWTX or BBIO?

Is EWTX or BBIO more profitable?

Which has preferable earnings and valuation, EWTX or BBIO?

Do insiders & institutionals believe in EWTX or BBIO?

Summary

How does Edgewise Therapeutics compare to Elanco Animal Health?

Does the media favor EWTX or ELAN?

Do insiders and institutionals believe in EWTX or ELAN?

Which has stronger valuation and earnings, EWTX or ELAN?

Is EWTX or ELAN more profitable?

Which has more volatility & risk, EWTX or ELAN?

Do analysts prefer EWTX or ELAN?

Summary

How does Edgewise Therapeutics compare to Summit Therapeutics?

Which has preferable valuation & earnings, SMMT or EWTX?

Does the media refer more to SMMT or EWTX?

Do insiders & institutionals hold more shares of SMMT or EWTX?

Is SMMT or EWTX more profitable?

Do analysts rate SMMT or EWTX?

Which has more volatility & risk, SMMT or EWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools